Policy & Regulation
PharmaJet's needle-free system used by University of Cambridge for COVID-19 clinical trial
19 January 2022 -

Injection technology company PharmaJet revealed on Tuesday that its Needle-free Injection System (NFIS) will be used in a clinical trial that will deliver a booster vaccine against COVID-19 virus variants.

The vaccine is reportedly developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK,

Under the University of Cambridge's Phase 1 clinical trial, the COVID-19 vaccine will be delivered exclusively with the PharmaJet Tropis Needle-free injection system, which was selected based on its ability to increase the efficacy of nucleic acid-based vaccines and therapeutics.

This is the 20th COVID-19 vaccine development programme using PharmaJet Needle-free Injection Systems as their method of delivery.